Marc Y. Donath

Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus

Claus M. Larsen, Mirjam Faulenbach, Allan Vaag et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text

Medicine, Endocrinology, Pharmacology +17

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Jean MacFadyen, Tom Thurén et al. · The Lancet · 2017 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets

Kathrin Maedler, Frédéric Ris, José Oberholzer et al. · Journal of Clinical Investigation · 2002 · 992 citations · Full text

Life Sciences, Cell Biology, Endocrinology +17

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

Helga Ellingsgaard, Irina Häuselmann, Beat Schuler et al. · Nature Medicine · 2011 · 918 citations · Full text

Life Sciences, Endocrinology, Physiology +17

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Paul M. Ridker, Jean MacFadyen, Peter Libby et al. · The Lancet · 2017 · 886 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +8